Drug Profile
CNTO 530
Alternative Names: CNTO-530Latest Information Update: 14 Aug 2018
Price :
$50
*
At a glance
- Originator Centocor
- Developer BioElectron Technology; Centocor Ortho Biotech
- Class Antianaemics; Antibodies; Recombinant fusion proteins
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemoglobinopathies; Mitochondrial disorders; Thalassaemia
Most Recent Events
- 01 Aug 2018 Edison Pharmaceuticals is now called BioElectron Technology
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Haemoglobinopathies in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Mitochondrial disorders in USA (Parenteral)